Antibody　drugs　have　been　used　to　treat　many　diseases,　and　to　date,　this　has　been　the　most　rapidly　growing　drug　class.　However,　the　lack　of　suitable　methods　for　real-time　and　high-throughput　monitoring　of　antibody　production　and　quality　control　has　been　a　hindrance　to　the　further　advancement　of　antibody　drugs　or　biosimilars.　Therefore,　we　herein　report　a　versatile　tool　for　one-step　fluorescence　monitoring　of　antibody　production　by　using　aptamer　probes　selected　through　the　in　vitro　SELEX　method.　In　this　case,　DNA　aptamers　were　selected　against　the　humanized　IgG1　antibody　drug　trastuzumab　with　high　specificity　and　affinity　with　a　Kd　value　of　aptamer　CH1S-3　of　10.3　nM.　More　importantly,　the　obtained　aptamers　were　able　to　distinguish　native　from　heat-treated,　whereas　antibodies　failed　this　test.　On　the　basis　of　the　advantages　of　rapid　detection　for　aptamers,　we　designed　aptamer　molecular　beacons　for　direct　and　sensitive　detection　of　trastuzumab　in　complex　samples.　Unlike　traditional　antibody-based　ELISA,　the　signal　was　observed　directly　upon　interaction　with　the　target　without　the　need　for　time-consuming　binding　and　multiple　washing　steps.　To　further　highlight　biomedical　applications,　the　use　of　aptamers　as　potential　tools　for　quality　control　and　traceless　purification　of　antibody　drugs　was　also　demonstrated.　Thus,　aptamers　are　shown　to　be　promising　alternatives　for　antibody　production　monitoring,　quality　control,　and　purification,　providing　technical　support　to　accelerate　antibody　drug　development.　Copyright　©　2020　American　Chemical　Society.